NCT01160250View on ClinicalTrials.gov

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

APPROVED_FOR_MARKETINGEXPANDED_ACCESS

Timeline

Start Date

July 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Basal Cell Carcinoma

Interventions

DRUG

vismodegib (GDC-0449)

Oral repeating dose

Trial Locations (11)

10029

New York

19104

Philadelphia

32174

Ormond Beach

37203

Nashville

43210

Columbus

48201

Detroit

77030

Houston

85258

Scottsdale

85259

Scottsdale

90025

Los Angeles

94305

Stanford

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY